TAO Synergies Inc. Files 8-K: Board Changes & Compensation

TL;DR

TAO Synergies Inc. filed an 8-K detailing board changes and executive compensation updates.

AI Summary

TAO Synergies Inc. announced on August 26, 2025, a change in its board of directors and executive compensation arrangements. The filing also includes information regarding Regulation FD disclosures and other events, with financial statements and exhibits provided. The company was formerly known as Synaptogenix, Inc. and Neurotrope Bioscience, Inc.

Why It Matters

Changes in a company's board and executive compensation can signal shifts in strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in board composition and executive compensation can introduce uncertainty regarding future strategic direction and financial performance.

Key Players & Entities

• TAO Synergies Inc. (company) — Registrant
• Synaptogenix, Inc. (company) — Former Company Name
• Neurotrope Bioscience, Inc. (company) — Former Company Name
• August 26, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share TAOX The Nasdaq
• $8.40 — f common stock, at an exercise price of $8.40 per share. The warrants will expire fiv

Filing Documents

• tm2524680d1_8k.htm (8-K) — 29KB
• tm2524680d1_ex99-1.htm (EX-99.1) — 10KB
• 0001104659-25-085770.txt ( ) — 207KB
• snpx-20250826.xsd (EX-101.SCH) — 3KB
• snpx-20250826_lab.xml (EX-101.LAB) — 33KB
• snpx-20250826_pre.xml (EX-101.PRE) — 22KB
• tm2524680d1_8k_htm.xml (XML) — 4KB

02 Departure of Directors or Certain Officers; Election of

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignations of Mr. Schechter and Dr. Tuchman On August 28, 2025, Jonathan Schechter resigned from his position as a member of the board of directors (the "Board") of TAO Synergies Inc. (the "Company") and as a member of all committees of the Board on which he serves. Mr. Schechter's resignation was voluntary and not the result of any disagreement with the operations, policies or practices of the Company. Additionally, on August 28, 2025, Dr. Alan Tuchman, M.D. resigned from his position as a member of the Board and as a member of all committees of the Board on which he serves. Mr. Tuchman's resignation was voluntary and not the result of any disagreement with the operations, policies or practices of the Company. Upon his resignation, Mr. Tuchman will continue to serve as the Company's Chief Medical Officer. Appointment of Mr. Ephron In connection with the aforementioned resignations, on August 29, 2025, the Company appointed Robert Ephron to the Board. Mr. Ephron joins the Company from JK Polk Holdings where he has served as an advisor in advertising and sales since 2024. Mr. Ephron was previously vice president of advertising and sales at Paramount from 2017 to 2023 and vice president of advertising and sales at Viacom from 2015 to 2017. Mr. Ephron received his Bachelor of Science from the University of Denver. Mr. Ephron will serve on the audit, compensation and nominating and corporate governance committees of the Board. In connection with his appointment to the Board, Mr. Ephron has waived his entitlement to an initial option grant upon joining the Board pursuant to the Company's non-employee director compensation policy. The Company is not aware of any transaction in which Mr. Ephron has an interest that would require disclosure under Item 404(a) of Regulation S-K.

01. Regulation FD

Item 7.01. Regulation FD. On August 26, 2025, the Company issued a press release announcing it has engaged Joseph Jacks as an advisor to its digital asset treasury strategy led by James Altucher. A copy of the press release is attached as Exhibit 99.1 hereto. The information in this Item 7.01 to this Current Report on Form 8-K, and in Exhibit 99.1 furnished herewith, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 8.01. Other Events. In connection with the engagement of Joseph Jacks, the Company entered into a consulting agreement with a term of one year with Mr. Jacks, pursuant to which the Company issued warrants exercisable for 100,000 shares of common stock, at an exercise price of $8.40 per share. The warrants will expire five years from the date of issuance. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated August 26, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TAO SYNERGIES INC. Date: August 29, 2025 By: /s/ Robert Weinstein Name: Robert Weinstein Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR